Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018.
allergic contact dermatitis
contact allergy
decyl glucoside
glucoside
lauryl glucoside
patch test
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
18
02
2022
revised:
04
04
2022
accepted:
30
04
2022
pubmed:
14
5
2022
medline:
20
10
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Alkyl glucosides are nonionic surfactants that are increasingly used in personal care products. To characterize positive patch test reactions to decyl glucoside (5% petrolatum, tested 2009-2018) and lauryl glucoside (3% petrolatum, tested 2017-2018). Retrospective analysis of patients tested by the North American Contact Dermatitis Group. Of 24,097 patients patch tested to decyl and/or lauryl glucoside, 470 (2.0%) had positive reactions. Compared with glucoside-negative patients, glucoside-positive patients had higher odds of occupational skin disease (13.4% vs 10.1%; P = .0207), history of hay fever (38.5% vs 31.6%; P = .0014), atopic dermatitis (39.0% vs 28.6%; P < .0001), and/or asthma (21.8% vs 16.5%; P = .0023). Most glucoside reactions (83.9%) were currently relevant. The most common source was personal care products (63.0%), especially hair products (16.5%) and skin cleansers (15.2%). Of 4933 patients tested to decyl and lauryl glucoside, 134 (2.7%) were positive to 1 or both; 43.4% (43 of 99) of decyl-positive patients were also positive to lauryl glucoside and 55.1% (43/78) of lauryl glucoside patients were also positive to decyl glucoside. The cohort predominantly reflects a referral population, and follow-up after testing was not captured. Glucoside positivity occurred in 2.0% of the tested patients. Reactions were often clinically relevant and linked to personal care products. Cross-reactivity was >40%.
Sections du résumé
BACKGROUND
Alkyl glucosides are nonionic surfactants that are increasingly used in personal care products.
OBJECTIVE
To characterize positive patch test reactions to decyl glucoside (5% petrolatum, tested 2009-2018) and lauryl glucoside (3% petrolatum, tested 2017-2018).
METHODS
Retrospective analysis of patients tested by the North American Contact Dermatitis Group.
RESULTS
Of 24,097 patients patch tested to decyl and/or lauryl glucoside, 470 (2.0%) had positive reactions. Compared with glucoside-negative patients, glucoside-positive patients had higher odds of occupational skin disease (13.4% vs 10.1%; P = .0207), history of hay fever (38.5% vs 31.6%; P = .0014), atopic dermatitis (39.0% vs 28.6%; P < .0001), and/or asthma (21.8% vs 16.5%; P = .0023). Most glucoside reactions (83.9%) were currently relevant. The most common source was personal care products (63.0%), especially hair products (16.5%) and skin cleansers (15.2%). Of 4933 patients tested to decyl and lauryl glucoside, 134 (2.7%) were positive to 1 or both; 43.4% (43 of 99) of decyl-positive patients were also positive to lauryl glucoside and 55.1% (43/78) of lauryl glucoside patients were also positive to decyl glucoside.
LIMITATIONS
The cohort predominantly reflects a referral population, and follow-up after testing was not captured.
CONCLUSION
Glucoside positivity occurred in 2.0% of the tested patients. Reactions were often clinically relevant and linked to personal care products. Cross-reactivity was >40%.
Identifiants
pubmed: 35551968
pii: S0190-9622(22)00788-5
doi: 10.1016/j.jaad.2022.04.058
pii:
doi:
Substances chimiques
Allergens
0
Cosmetics
0
Glucosides
0
Surface-Active Agents
0
Petrolatum
8009-03-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1041Informations de copyright
Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest Dr Warshaw reports investigator-initiated grant from WEN by Chaz Dean and has served as a consultant for WEN by Chaz Dean and Noven Pharmaceuticals. Dr Atwater has received a Pfizer Independent Grant for Learning & Change, has consulted for Henkel, and is employed by Eli Lilly and Company. Dr Taylor owns noncontrolling common shares of stock in Astra Zeneca, Cigna, Merck, Johnson & Johnson, and Opko Health; has consulted for Kao Brands and Monsanto (Bayer); is a member of the Cosmetic Ingredient Review Steering Committee; and has a nondependent child employed by Pfizer. Dr Sasseville receives royalties from UpToDate (Wolters Kluwer Health). Author Xiong and Drs DeKoven, Pratt, Maibach, Belsito, Silverberg, Reeder, Zug, Fowler, DeLeo, Houle, and Dunnick have no conflicts of interest to disclose.